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Abstract: Bacteria are isolated in more than 50% of exacerbations of chronic bronchitis (CB) 
and chronic obstructive pulmonary disease (COPD). The most prevalent respiratory pathogens 
include Gram-positive (Streptococcus pneumoniae) and Gram-negative (Haemophilus inﬂ  uenzae, 
Moraxella catarrhalis) microorganims. Moxiﬂ  oxacin is a fourth-generation ﬂ  uoroquinolone 
that has been shown to be effective against respiratory pathogens, including atypicals and those 
resistant to most common antibiotics. The bioavailability and half-life of moxiﬂ  oxacin provides 
potent bactericidal effects at a dose of 400 mg once daily. Among the ﬂ  uoroquinolones, the 
ratio of the area under the concentration-time curve (AUC) to minimal inhibitory concentration 
of moxiﬂ  oxacin is the highest against S. pneumoniae. Moxiﬂ  oxacin has demonstrated better 
eradication in exacerbations of CB and COPD compared with standard therapy, in particular, 
with macrolides. Patients treated with moxiﬂ  oxacin showed a prolonged time to the next 
exacerbation and observational studies suggest that moxiﬂ  oxacin induces a faster release of 
symptoms of exacerbation. Some guidelines recommend the use of moxiﬂ  oxacin as ﬁ  rst-line 
therapy in bacterial exacerbations in patients with moderate to severe COPD and in patients with 
mild COPD with risk factors. The current article reviews the use of moxiﬂ  oxacin in bacterial 
exacerbations of CB and COPD.
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Introduction
After cardiovascular disease, respiratory diseases rank second in terms of mortality, 
incidence, prevalence, and costs. The European prevalence of chronic obstructive pulmonary 
disease (COPD) ranges from 2% in France and the UK, to 9% in Spain (Sobradillo et al 
2000), and 10% in Germany and Italy (Loddenkemper 2003). Moreover, a European-
wide increase in the prevalence and mortality of COPD and other smoking-related diseases, 
particularly in women, is projected for the coming decades (Peto et al 1992). Chronic 
bronchitis (CB), a component of COPD, usually associated with frequent exacerbations, 
is even more prevalent; as an example, 4.1% of the French population aged 25+ years 
develop this disease (Huchon et al 2002). Nonetheless, the prevalence of CB differs between 
countries. In a recent study of young European adults, the prevalence of CB in subjects aged 
20–44 years ranged from 0.7% in the UK to 9.7% in Spain (De Marco et al 2004), with the 
prevalence being directly associated with smoking prevalence (Cerveri et al 2001).
Due to the high prevalence and chronic course of these conditions, COPD and CB 
represent a great burden to society. The mean annual direct medical costs of a COPD 
patient are an estimated  1800, with 42% of the costs being due to hospitalisations, 
most because of exacerbations (Miravitlles et al 2003a). Each exacerbation treated 
in the community has a mean cost of  175, but costs are higher for complicated 
exacerbations requiring hospital admission (Miravitlles et al 2002).
In addition, COPD and CB are debilitating conditions affecting fundamental aspects 
of everyday life including normal physical exertion, work, and social and family International Journal of COPD 2007:2(3) 192
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activities (Murray and Lopez 1997). Chronic lung disease 
thus has substantial effects on health-related quality of life 
(HRQoL), with increasing CB severity and factors such as 
frequency and nature of exacerbations being associated with 
increasing symptoms and deteriorating HRQoL (Seemungal 
et al 1998; Miravitlles et al 2004a). HRQoL has been found to 
be signiﬁ  cantly adversely affected during exacerbations with 
increased anxiety about breathlessness and the coughing up 
of phlegm in public (Nicolson and Anderson 2000).
Bacterial are isolated in 50%–75% of exacerbations 
(Miravitlles 2002a; Papi et al 2006). Because of the difﬁ  culties 
in establishing a bacteriological diagnosis of respiratory tract 
infections (RTIs) in ambulatory clinical practice, it is common 
practice to commence antibiotic treatment empirically. In 
an analysis of initial antibiotic treatment in Europe for all 
infections, including RTIs, 85% of these therapies were started 
empirically (Halls 1993). In view of the limits of the spectrum 
of activity of some antibiotics, as well as the increasing 
prevalence of bacterial resistance to older generation agents, 
multiple antibiotics are administered in some cases of RTIs or 
when resistant or polymicrobial infection is suspected (Smith 
et al 1999). There is a continued need to ﬁ  nd antibiotics that 
can be used in empiric treatment regimens so that the patient 
responds rapidly and the risk of development of resistance 
is limited.
Moxifloxacin hydrochloride (Avelox®, Bayer AG) 
is a ﬂ  uoroquinolone that has been shown to be effective 
against Moraxella catarrhalis, Haemophilus inﬂ  uenza, and 
multi-drug resistant pneumococcal strains (Blondeau 1999; 
Saravolatz et al 2001; Miravitlles 2005). Moxifloxacin 
is strongly targeted to alveolar tissue (Soman 1999 et al; 
Miravitlles 2000), and has shown rapid initial killing and 
eradication rates for pneumococcal bacteria (Lister and 
Sanders 2001).
This paper will focus on recent advances in the study 
of antimicrobial treatment of exacerbations of CB and 
COPD with moxifloxacin. In this respect, new trials 
have documented improved outcomes related to time to 
resolution of symptoms and extended time to the next 
exacerbation. These new outcomes derive from the better 
understanding of the natural history of CB and COPD 
and their exacerbations.
Pharmacology
Mechanism of action
Moxiﬂ  oxacin is a forth generation ﬂ  uoroquinolone with 
bactericidal activity as a result of its interference with 
topoisomerase II (DNA gyrase) and IV (Scheld 2003). 
Topoisomerases are essential enzymes which play a 
crucial part in the replication, transcription, and repair 
of bacterial DNA. Topoisomerase IV is also known 
to influence bacterial chromosome division. Kinetic 
investigations have demonstrated that moxifloxacin 
exhibits a concentration-dependent killing rate; minimum 
bactericidal concentrations (MBC) were found to be within 
the range of the minimum inhibitory concentrations (MIC) 
(Stass 1999; Krasemann et al 2001).
Antimicrobial activity
Moxiﬂ  oxacin demonstrates excellent in vitro activity (as 
assessed by MIC90 concentrations of 0.06 to 0.25 mg/L) 
against all the predominant respiratory pathogens including 
Gram-positive (Streptococcus pneumoniae), Gram-negative 
(H. inﬂ  uenzae, M. catarrhalis), anaerobic (peptostreptococci 
or Prevotella spp.), and atypical strains (C. pneumoniae, 
M. pneumoniae). Against both beta-lactamase positive 
and negative M. catarrhalis and H. influenzae, MIC90 
values to moxifloxacin were <0.06 μg/mL. Similarly, 
moxiﬂ  oxacin MIC90 values ranged from 0.06 to 0.25 μg/mL 
against clinical isolates of S. pneumoniae regardless of 
penicillin susceptibility (Woodcock 1997; Blondeau 1999) 
(Table 1).
Pharmacokinetics
Following oral administration moxifloxacin is rapidly 
and almost completely absorbed, with an absolute 
bioavailability of approximately 91% (Stass et al 2001). 
Its penetration into pulmonary tissues is excellent 
and concentrates in alveolar macrophages (Table 2). 
Following a 400 mg oral dose, peak concentrations of 
3.1 mg/L are reached within 0.5–4 hours post admin-
istration. Peak and trough plasma concentrations at 
steady-state (400 mg once daily) are 3.2 and 0.6 mg/L, 
respectively. Moxifloxacin is rapidly distributed to extra-
vascular spaces; and an area under the concentration-time 
curve (AUC) of 35 mg·h L–1 is observed after a dose of 
400 mg. Moxifloxacin is mainly bound to serum albumin. 
In vitro and ex vivo experiments have shown a protein 
binding of approximately 40%–42%, independently of 
the concentration of the drug (Soman et al 1999; Sullivan 
et al 1999).
Moxiﬂ  oxacin is eliminated from plasma with a mean 
terminal half-life of approximately 12 hours (Stass 1999). 
After a 400 mg dose, recovery of parent compound and 
metabolites of moxiﬂ  oxacin from urine and feces totals 
approximately 96% (Table 3).International Journal of COPD 2007:2(3) 193
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The pharmacokinetic and pharmacodynamic parameters 
for antibacterial agents can be integrated into the ratio of the 
AUC to MIC90, or area under the inhibition curve (AUIC), 
ie, the AUC/MIC normalized for 24 hours (Schentag 
et al 1996).
Agents with a low Cmax, short t1/2 and low in vitro activity 
against a speciﬁ  c pathogen (viz: higher MIC90 values) have a 
lower AUIC than those with high Cmax, prolonged t1/2 and high 
in vitro activity. Quinolones with AUIC values above 85–125 
and Cmax to MIC ratios of 8–10 have been associated with better 
clinical and bacteriological cure rates compared with agents 
with lower AUIC values (Forrest et al 1993). High AUIC 
values indicate rapid eradication of pathogens and a reduced 
likelihood of resistance development, as pathogens are killed 
before they have time to mutate (Schentag et al 1996).
Compared with other fluoroquinolones, moxifloxacin 
has the highest AUIC ratio against S. pneumoniae 
(192–400 35 mg·h L–1) (Wise 1999) (Table 3). Despite 
achieving good tissue penetration, levofloxacin is only 
moderately active against S. pneumoniae, whereas 
gatifloxacin is more bactericidal but only achieves modest 
tissue levels. Levofloxacin does not have the chemi-
cal structure of moxifloxacin to fight resistance, eg, a 
methoxy moiety at position C-8 – a substitution that has 
been shown to select for mutants much less frequently 
than a hydrogen moiety (Wise 1999). In addition, moxi-
floxacin has a 7-azabicyclo side chain that makes it more 
difficult to efflux the antibiotic out of the bacterial cell 
(Wise 1999).
The approved dose and regimen of oral moxiﬂ  oxacin 
for the indication of exacerbations of CB is: 400 mg orally 
once daily for 5–7 days.
Efﬁ  cacy of moxiﬂ  oxacin in 
exacerbations of chronic bronchitis 
and COPD
Registration clinical trials
The clinical program for moxiﬂ  oxacin included four studies 
comparing the efﬁ  cacy and safety of moxiﬂ  oxacin (400 mg 
once daily, 5 days) with either clarithromycin (500 mg 
twice daily, 7–10 days) or cefuroxime-axetil (500 mg twice 
daily, 10 days) in 2381 patients with exacerbations of CB 
(Miravitlles 2005).
The clinical and bacteriological success rates 7–14 days 
post-treatment were comparable between the three treatment 
groups. However, there was a trend towards improved 
bacteriological success after 5 days of moxiﬂ  oxacin therapy 
Table 1 Minimum inhibitory concentrations (MIC) of moxiﬂ  oxacin and other quinolones against common respiratory pathogens
 MIC90 (mg/L)
Bacterium Moxiﬂ  oxacin  Ciproﬂ  oxacin  Levoﬂ  oxacin  Trovaﬂ  oxacin
S. pneumoniae     
 penicillin-sensitivea  0.06–0.25  1–2 1–2 0.12–0.25
 penicillin-resistantb  0.12–0.25  1–2 1–2 0.12–0.25
S. aureus     
 methicillin-sensitive  0.12  0.5–1  0.25  0.06
 methicillin-resistant  2  32–128  16  2
M. catarrhalis     
  beta-lactamase  positive  0.012–0.06 0.015–0.06 0.06–0.094 0.03
  beta lactamase negative  0.012–0.06  0.015–0.06  0.06  0.03
H. inﬂ  uenzae     
 beta-lactamase  positive  0.03–0.06  0.015–0.03  0.03–0.47  0.015
  beta lactamase negative  0.03–0.06  0.015–0.03  0.03–0.32  0.015
Adapted from Blondeau (1999).
apenicillin sensitive indicates a penicillin MIC of <0.06 μg/mL.
bpenicillin resistant or non-susceptible indicates an MIC >0.1 μg/mL.
Table 2 Tissue concentrations by site 10 hours after oral ad-
ministration of 400 mg of moxiﬂ  oxacin
Site  Tissue concentration  Plasma ratio
Plasma 3.1  mg/L  n/a
Saliva 3.6  mg/L  0.75–1.3
Blister ﬂ  uid  1.61 mg/L  1.71
Bronchial mucosa  5.4 mg/kg  1.7–2.1
Alveolar Macrophages  56.7 mg/kg  18.6–70.0
Epithelial lining ﬂ  uid   20.7 mg/L  5–7
Interstitial ﬂ  uid  1.0a mg/L  0.8–1.4a, b
Data from Stass (1999); Stass et al (2001); Sullivan et al (1999).
aunbound concentration.
bfrom 3 hours up to 36 hours post dose.
n/a, not applicable.International Journal of COPD 2007:2(3) 194
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compared with 7–10 days of clarithromycin treatment. The 
three treatment regimens were also similar with respect 
to eradication of S. pneumoniae and M. catarrhalis. In 
contrast, moxiﬂ  oxacin showed improved eradication rates 
against H. inﬂ  uenzae (129/132, 97%) as compared with 
clarithromycin (62/86, 72%) (Niederman et al 2006). Taken 
together, the studies of the clinical program demonstrated that 
treatment with moxiﬂ  oxacin 400 mg once daily for 5 days 
achieves a clinical response rate of 89% and a bacteriological 
response rate of 87% (Miravitlles 2005).
Clinical studies of antimicrobials in exacerbations of 
CB such as those performed in the original clinical program 
have been limited by factors such as inadequate information 
on patient condition prior to the exacerbation and lack of 
long-term follow-up, as well as a lack of prospective control 
for steroid use, which can positively affect the outcome of the 
episode (Miravitlles and Torres 2004a), and for prognostic 
factors that can have a negative impact (Dewan et al 2000; 
Miravitlles 2001a) (Table 4). After the registration trials, 
new studies have been designed to evaluate the clinical 
efﬁ  cacy of moxiﬂ  oxacin in different patient populations 
with exacerbations of chronic bronchial disease. In parallel, 
new outcomes have been analyzed in this new generation 
of clinical trials.
Clinical efﬁ  cacy of moxiﬂ  oxacin: 
short-term outcomes
The MOSAIC study (Wilson et al 2004, 2006) was a 
multicenter, multinational, randomized study of two 
parallel treatment arms including outpatients aged 45 
years with stable CB, history of smoking of 20 packs/
year, 2 documented exacerbations in the previous year, 
and FEV185% of predicted value. Patients with a severe 
exacerbation of CB within 12 months of enrolment were 
randomized to receive either oral moxiﬂ  oxacin 400 mg 
once daily for 5 days or one of the comparators: amoxicillin 
500 mg tid for 7 days, clarithromycin 500 mg bid for 7 days 
or cefuroxime-axetil 250 mg bid for 7 days. Patients were 
assessed at screening, end of treatment and 7–10 days after 
treatment, and were contacted by phone monthly until a new 
exacerbation occurred or up to a maximum of 9 months. 
Clinical cure was deﬁ  ned as a return to pre-exacerbation 
status, and clinical success as cure and improvement 
combined, overall and by strata of steroid use and prognostic 
factors. Other efﬁ  cacy measures were needed for further 
antimicrobials, time to next exacerbation, and bacteriological 
treatment success. Of 1935 enrolled patients, 733 (37.9%) 
had severe (Anthonisen type I) exacerbation within 12 
months of screening and were randomized; 730 receiving 
either moxiﬂ  oxacin (n = 354) or comparator (n = 376). 
Clinical success was seen in 83.0%–87.6% of patients across 
treatment arms and populations, with statistical equivalence 
in all populations except a signiﬁ  cant difference in favor 
of moxiﬂ  oxacin patients not receiving steroids. However, 
Table 4 Risk factors for relapse after ambulatory treatment of 
exacerbations of chronic bronchitis and COPD
1.   Risk factors for frequent exacerbations (more than two
per year)
  Increasing  age
  Severity  of  FEV1 impairment
    Chronic bronchial mucus hypersecretion
  Frequent  past  exacerbations
    Daily cough and wheeze
  Bronchitic  symptoms
2. Risk factors for relapse
  Coexisting  cardiopulmonary  disease
    Increasing number of previous visits to the GP for respiratory
    problems
    Increasing number of previous exacerbations
  Increasing  baseline  dyspnoea
  Severity  of  FEV1 impairment
    Use of home oxygen
3. Risk factors for hospital admission
  Signiﬁ  cant comorbidities
  Severity  of  FEV1 impairment
    High admission rates for previous exacerbations
    Three or more admissions previous year
  Underprescription  of  LTOT
    Lack or reduction in physical activity
From Adams et al (2000); Dewan et al (2000); Miravitlles (2000b); Miravitlles et al 
(2001a, b); Prescott et al (1995); Seemungal et al (1998).
Abbreviations: LTOT,  long-term oxygen therapy.
Table 3 Main pharmacokinetic/pharmacodynamic parameters of 
moxiﬂ  oxacin after an oral dose of 400 mg
Bioavailability 90%
Cmax 3–4  mg/L
Tmax 1–2  h
Mean half-life  13 h
Binding to plasma proteins  <40%
Steady state volume of distribution  2–3 L/kg
Renal clearance  24–53 mL/min
Total body clearance  179–246 mL/min
AUC 35–45  mg.h  L–1
Cmax/MIC90 (pneumococcus)  25–35
AUC24h/MIC90 or AUIC (pneumococcus)  192–400 mg.h L–1
Data from Stass (1999); Stass et al (2001).
Abbreviations: Cmax, maximal or peak plasma concentration; Tmax, time to Cmax; 
AUC, area under the curve; AUIC, area under the inhibition curve; MIC, minimum 
inhibitory concentration.International Journal of COPD 2007:2(3) 195
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clinical cure rates were signiﬁ  cantly higher with moxiﬂ  oxacin 
(70.9%) compared with the comparators (62.8%) (95% 
conﬁ  dence interval (CI) of the difference = 0.3%–15.6%); 
the clinical cure rate was also signiﬁ  cantly greater in the 
moxiﬂ  oxacin arm when analyzed by prognostic factors of 
age, airway obstruction, number of exacerbations of CB 
in the previous year, duration of CB and cardiopulmonary 
comorbidity (Wilson et al 2004).
Bacterial eradication with moxiﬂ  oxacin in bacterio-
logically evaluable patients was signiﬁ  cantly higher with 
moxiﬂ  oxacin compared with the control antibiotics (91.5% 
vs 81%; 95% CI = 0.4%–22%) (Wilson et al 2004). Bacterial 
eradication with moxiﬂ  oxacin has been demonstrated to be 
superior compared with macrolides. In a pooled analysis of 
moxiﬂ  oxacin phase III trials compared with macrolide agents 
in eradication of H. inﬂ  uenzae, the results showed superiority 
of moxiﬂ  oxacin against both azithromycin and clarithro-
mycin. Eradication of H. inﬂ  uenzae with moxiﬂ  oxacin was 
93% (133/143) compared with 73.2% (109/149) with mac-
rolides, p = 0.001. Considering both macrolides separately, 
eradication rates were 96.8% with moxiﬂ  oxacin vs 84.6% 
with azithromycin (p = 0.019) and 90.1% with moxiﬂ  oxacin 
vs 64.3% with clarithromycin (p = 0.001) (Niederman et al 
2006) (Figure 1).
The results of the MOSAIC trial also showed that up to 
14.8% of patients treated with a comparator antibiotic required 
a second prescription of antibiotics to control symptoms of 
exacerbation, compared with only 8.8% of patients randomized 
to receive moxiﬂ  oxacin (p = 0.03) (Wilson et al 2004).
Although initially designed to demonstrate non-inferiority 
of moxiﬂ  oxacin over standard therapy, the MOSAIC study 
was the ﬁ  rst clinical trial to demonstrate the superiority of 
an antibitic, moxiﬂ  oxacin, over the comparators in clinical 
cure and bacteriological eradication rates.
A recent publication has provided a systematic analysis and 
meta-analysis of published clinical trials with moxiﬂ  oxacin in the 
treatment of exacerbations of CB up to June 2005 (Miravitlles 
et al 2007a) with the objective to determine the superiority of 
moxiﬂ  oxacin over standard therapy in this indication. A total 
of 45 studies were identiﬁ  ed, but only 9 fulﬁ  lled the inclusion 
criteria in the meta-analysis. Of them, 5 were randomized and 
double-blind and 4 were randomized and open labeled.
Bacteriological eradication rate
P = 0.019 P   = 0.001
Moxifloxacin Azithromycin Clarithromycin
96.8
84.6
90.1
64.3
0
20
40
60
80
100
B
a
c
t
e
r
i
a
l
 
e
r
a
d
i
c
a
t
i
o
n
,
 
%
 
p
a
t
i
e
n
t
s
 
(
n
/
N
)
(60/62)
(55/65)
(73/81)
(54/84)
Figure 1 Eradication rates for H. inﬂ  uenzae in exacerbations of CB treated with moxiﬂ  oxacin or macrolides. Derived from Niederman et al (2006).International Journal of COPD 2007:2(3) 196
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All studies concluded that the efﬁ  cacy of treatment with 
moxiﬂ  oxacin was at least as good as treatment with the com-
parator. One of the studies concluded that eradication and 
cure rates were superior with moxiﬂ  oxacin versus compara-
tors, as highlighted above (Wilson et al 2004).
The global analysis included 3905 randomized patients 
and showed an aggregated superior clinical success rate of 
moxiﬂ  oxacin of 1.5% (95% CI = –0.4%–3.4%) which did 
not reach statistical signiﬁ  cance, but showed a trend towards 
a better clinical outcome with moxiﬂ  oxacin (Figure 2). It is 
of note that these results were obtained from a combined 
analysis of studies individually designed to show equivalence 
between both treatment arms and without enough statistical 
power to demonstrate superiority.
Long-term outcomes: prevention
of exacerbations with moxiﬂ  oxacin
The most important unmet need in the treatment of 
exacerbations of COPD is the prevention of recurrence 
(Miravitlles et al 2007b). One of the characteristics of the 
MOSAIC trial was the follow-up period of up to 9 months 
after recovery from the exacerbation. The hypothesis was that 
a better eradication rate with moxiﬂ  oxacin would translate 
into a prolonged time to the next exacerbation. In 405 patients 
with new exacerbations during the follow-up period, the 
mean time to event was 10 days longer with moxiﬂ  oxacin 
treatment (127.6 ± 68.1 days) than comparators (116.7 ± 68.8), 
with more patients receiving the comparator having new 
exacerbations within 60 days of treatment (51/208, 24.5%) 
than moxiﬂ  oxacin (31/197, 15.7%). The log rank test showed 
a signiﬁ  cant difference in favor of moxiﬂ  oxacin for up to 5 
months of follow-up (p = 0.03) (Wilson et al 2004).
In a secondary analysis, the authors attempted to identify 
the variables independently and signiﬁ  cantly associated 
with a prolonged time to the next exacerbation. Treatment 
with moxiﬂ  oxacin was associated with a prolonged time to 
recurrence (hazard ratio for recurrence with moxiﬂ  oxacin 
versus comparators 0.82; 95% CI = 0.68–0.98) (Wilson 
et al 2006).
This effect of moxiﬂ  oxacin on time to relapse has not been 
observed with other ﬂ  uoroquinolones. In a recent study, levo-
ﬂ  oxacin was compared with clarithromycin in a group of 434 
patients with exacerbations of CB. After a 1-year follow-up, 
no differences in time free from exacerbation were observed 
between patients treated with levoﬂ  oxacin (mean of 100.5 
days) or clarithromycin (95 days), p = 0.32 (Lode et al 2004). 
These results may be the consequence of a lower antibacterial 
activity of levoﬂ  oxacin compared to moxiﬂ  oxacin or more 
likely to the inclusion of a milder patient population in the 
latter study, making clinical differences against macrolides 
less likely (Miravitlles and Torres 2004b).
The rationale for the prevention of exacerbations with 
moxiﬂ  oxacin derives from a combination of at least three 
different factors: a) an immunomodulatory effect of the drug 
(Dalhoff and Shalit 2003); b) the rapid and more complete 
eradication prevents epithelial damage and restores the 
local defence mechanisms of the bronchial mucosa (De 
Benedetto and Sevieri 2006); c) as a consequence of the better 
eradication, fewer viable pathogens remain in the bronchial 
tissue after antimicrobial treatment, requiring longer for 
the bacterial population to increase sufﬁ  ciently to induce 
a new exacerbation (Chodosh 2005). This last hypothesis 
is also known as the “fall and rise” hypothesis of bacterial 
exacerbation of CB (Miravitlles 2002b). In clinical trials with 
Author Effect Min Cases
Combined (Fixed effects)
Combined (random effects)
Heterogeneity: X2= 8.65 GL=8 p=0.37 Control superior          Moxifloxacin superior
Max. −0,25 −0,13 0,13 0,25 0,00 p
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De Abate 2000
Wilson  1999
Wilson  2004
Grassi 2002
Kreis  2000
Starakis 2004
−0,016 −0,070
−0,056
−0,105
−0,062
−0,041
−0,042
−0,031
−0,001
−0,004
−0,004
−0,011
−0,006
−0,003
0,008
0,016
0,043
0,045
0,037 0,553
0,643
0,909
0,926
0,762
0,595
0,031
0,055
0,120
0,125
0,257
0,034
0,094
0,057
0,073
0,087
0,116
0,154
0,033
0,034
0,056
0,004
0,015
0,015
0,076
272
461
464
423
399
512
572
3905
3905
649
153
Figure 2  Results of the meta-analysis of clinical trials with moxiﬂ  oxacin in exacerbations of CB and COPD. Data obtained from 9 studies including 3,905 patients. Repro-
duced with permission from Miravitlles M, Molina J, Brosa M. 2007a. Clinical efﬁ  cacy of moxiﬂ  oxacin in the treatment of exacerbations of chronic bronchitis: a systematic 
review and meta-analysis. Arch Bronconeumol, 43:22–28. Copyright © 2007 Elsevier.International Journal of COPD 2007:2(3) 197
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antibiotics, a prolonged time to the next exacerbation has been 
observed in patients who eradicate the bronchial pathogen 
after an exacerbation compared with those who cured the 
exacerbation but without effective eradication (Chodosh et al 
1998). According to the “fall and rise” hypothesis, patients 
who effectively eradicate bacteria would need a longer time 
to achieve the threshold of bacterial counts compared with 
patients who cured the exacerbation but in whom bacteria 
still persisted after antibiotic treatment (Miravitlles 2002b). 
This hypothesis would also explain why patients with 
acute exacerbations may be clinically cured even without 
eradication of the bacterial pathogen (Wilson et al 1999). 
This is not proof that this particular bacterium is not the cause 
of the exacerbation, but does demonstrate that the antibiotic 
only needs to reduce bacterial counts to below the threshold to 
eliminate symptoms. Nevertheless, if eradication also occurs, 
the time for a number of bacteria above the threshold to be 
reached will be longer (Figure 3).
The quantitative or “fall and rise” hypothesis may 
explain the basic mechanism of bacterial exacerbations in 
patients with chronic bronchial colonisation and frequent 
exacerbations. In this group of patients, the change in the 
serotype of the colonising bacteria may act as a trigger 
that initiates profileration of microorganisms in some 
cases. The “fall and rise” can also explain relapses when 
bacteria have not been eradicated after antibiotic treatment 
of the exacerbation. In contrast, the change of serotype of 
infective bacteria may be crucial in patients who do not 
suffer frequent exacerbations, ie, less than two in a year. 
It is difﬁ  cult to explain the appearance of an exacerbation 
more than four months after a preceding episode based only 
on bacterial growth in the airways without any precipitating 
factor, such as change in serotype (Sethi et al 2002). New 
evidence is required on the complex relationship between 
microorganisms and the host, particularly considering that 
important therapeutic implications may be derived from 
these ﬁ  ndings. In fact, if the new exacerbation is caused by 
the regrowth of the same bacteria that remained unkilled, 
the logical approach to treatment would be to use a different 
antibiotic and rotation of antibiotics should be recommended 
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Figure 3  The “fall and rise” hypothesis of bacterial exacerbations of COPD.
Note: Some patients with COPD have bacterial colonization of the lower airways. This colonisation is usually due to potentially pathogenic microorganisms (PPMs) in 
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host. When this proliferation exceeds a threshold, symptoms of acute exacerbation may appear. Under antimicrobial therapy, CFU/mL decrease, and when the threshold is 
crossed, clinical symptoms will disappear. When the intensity and speed of bactericidal activity of the antimicrobial increases (AB2), recovery will be more rapid and time 
to the next exacerbation will be prolonged. Antimicrobial activity will produce a “fall” in bacterial concentrations, which if not completely eradicated after the pressure of 
antimicrobial disappears, will “rise” again. Some modifying factors (risk factors, see Table 4) may change the threshold of clinical symptoms. 
Modiﬁ  ed from Miravitlles (2002b).International Journal of COPD 2007:2(3) 198
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to prevent bacteriological failure and the development of 
resistance. In contrast, if new exacerbations are caused by 
the acquisition of new strains, the same antibiotic can be used 
in repeated exacerbations without concern about increased 
exposure to the same antibiotic. 
Speed of recovery after antibiotic 
treatment of an exacerbation
Fast recovery of the symptoms of an exacerbation is highly 
demanded by patients (Miravitlles et al 2007b). Antibiotics 
that exhibit faster bacterial killing in vitro should provide 
faster relief of symptoms in patients with exacerbations of 
CB and COPD.
Observational studies and cross-sectional analyses in 
patients with CB and COPD have suggested that patients 
recover from symptoms of exacerbations more rapìdly with 
moxiﬂ  oxacin than with other commonly used treatments 
(Kreis et al 2000; Miravitlles et al 2003b, 2004b).
One large, multicenter comparative study using a 2-year 
protocol (IMPAC study) showed a signiﬁ  cant reduction 
in the time to recovery from exacerbations of moderate to 
severe COPD (Miravitlles et al 2003b). In 441 patients with 
COPD, all with a FEV1 <50% predicted (mean FEV1 = 36% 
predicted), the investigators treated 614 exacerbations with 
moxiﬂ  oxacin (exacerbations = 111) and 503 with either 
amoxicillin/clavulanate, cefuroxime, or clarithromycin. 
Moxiﬂ  oxacin was available in the second study year only. 
In year 2, exacerbations treated with moxiﬂ  oxacin resulted 
in complete recovery from symptoms in a mean of 4.6 days, 
compared with 5.8 days for the other treatments administered 
(p = 0.02). In the longitudinal analysis of 27 patients treated 
with moxiﬂ  oxacin who had received other treatments in 
year 1, the mean time to recovery from exacerbations was 
signiﬁ  cantly reduced from a mean of 6.8–3.7 days (p = 0.02). 
These results were conﬁ  rmed in another study, the EFEMAP 
study (Estudio FarmacoEconómico de Moxiﬂ  oxacino en las 
Agudizaciones de la EPOC), with mild to moderate COPD 
patients in primary care centers (Miravitlles et al 2004b). 
A total of 1456 patients with COPD (mean FEV1 = 52% 
predicted) received either moxiﬂ  oxacin (n = 575), amoxicillin/
clavulate (n = 460), or clarithromycin (n = 421). Clinical 
success was observed in 97.2%, 93.1%, and 94.4% of the 
cases, respectively, without signiﬁ  cant differences among 
the groups. However, symptoms of purulence and the volume 
of expectoration resolved a mean of one day earlier with 
moxiﬂ  oxacin compared with the other groups (Miravitlles 
et al 2004b). In a secondary analysis of the EFEMAP study, 
the factors associated signiﬁ  cantly and independently with a 
slow recovery (more than 5 days) were the use of long-term 
oxygen therapy (odds ratio (OR) = 1.97; 95% CI = 1.35–2.85); 
the increased use of rescue medication with short-acting 
beta-2 agonists (OR = 1.51; 95% CI = 1.17–1.92); and the 
use of amoxicillin/clavulanate or clarithromycin compared 
with moxiﬂ  oxacin (OR = 2.94; 95% CI = 2.22–3.84 and 
OR = 2.43; 95% CI = 1.17–3.22, respectively) (Miravitlles 
et al 2005). Although all studies consistently indicate a faster 
resolution of symptoms of exacerbations with moxiﬂ  oxacin 
compared to other frequently used antibiotics, these results 
must be interpreted with caution because they derive from 
observational studies and, as such, are subjected to possible 
sources of biases.
A economic analysis derived from the results of the 
EFEMAP study has shown that exacerbations treated 
with moxiﬂ  oxacin generated a direct medical cost similar 
to those treated with amoxicillin/clavulanate ( 111.46; 
95% CI =  73.4–149.5 compared with  109.45; 95% CI 
=  68.2–150.7, respectively); and lower, although not 
signiﬁ  cantly, than those treated with clarithromycin (
138.95; 95% CI =  89.4–188.5). These differences were 
mainly due to the higher costs associated with relapse in 
the group treated with clarithromycin (Llor et al 2004) 
(Figure 4). 
Clinical efﬁ  cacy of moxiﬂ  oxacin 
in patients belonging to risk groups
Failure rates after ambulatory treatment derive from 
clinical trials on antibiotics in CB and range from 7% to 
12%. Nevertheless, these results cannot be extrapolated 
to everyday practice, since patients included in clinical 
trials consist of CB patients and include subjects with 
ages ranging from 18 to 90 years, a signiﬁ  cant proportion 
of never smokers, and individuals without ventilatory 
impairment (not COPD) (Miravitlles and Torres 2004b). 
However, more recently, some studies have addressed 
treatment failure in observational “real-life” studies and 
showed a failure rate ranging from 12% to 26% (Dewan 
et al 2000; Adams et al 2000; Miravitlles 2000b; Miravitlles 
et al 2001a; Macfarlane et al 2001). Identiﬁ  cation of risk 
factors for failure may permit the implementation of more 
aggressive broad spectrum treatment and closer follow-
up. In a further step, risk factors associated with relapse 
should be incorporated into management guidelines to 
aid in identifying at-risk patients. Among the risk factors, 
severity of the underlying pulmonary disease is probably 
the most important. A summary of the main risk factors for 
relapse is presented in Table 4.International Journal of COPD 2007:2(3) 199
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Some of the studies included in the meta-analysis of 
clinical trials evaluated the efﬁ  cacy of moxiﬂ  oxacin in 
patients belonging to different risk groups. In a study 
comparing moxifloxacin and amoxicillin-clavulanate 
(Schaberg et al 2001), individuals older than 60 years 
showed a signiﬁ  cantly better success rate with moxiﬂ  oxacin 
(p = 0.048) and a tendency towards a better outcome with 
moxiﬂ  oxacin in patients with cardiopulmonary comorbidity 
(p = 0.054). The MOSAIC study has also demonstrated 
the superiority of moxiﬂ  oxacin over the comparators in 
elderly patients and those with a higher number of previous 
exacerbations (Wilson 2006). Table 5 presents the results 
of moxiﬂ  oxacin and comparators in patients belonging to 
different risk groups.
The main studies of moxifloxacin for the treatment 
of exacerbations of CB and COPD are summarized in 
Table 6.
Safety
Adverse events
Moxiﬂ  oxacin has shown a highly favorable safety and 
tolerability profile in clinical trials as well as in the 
clinical setting. In a meta-analysis of data from clinical 
trials and post-marketing surveillance comprising over 
25 million patient treatments, the most frequent adverse 
events reported in clinical trials were nausea (7.1%), 
diarrhea (5.2%), and dizziness (2.6%) following the 
administration of a dosage of 400 mg, once daily (Ball 
et al 2004). In all cases the frequency of side-effects was 
not statistically different to that of the comparators. There 
was no evidence that moxiﬂ  oxacin caused disturbances in 
glucose metabolism in patients with or without diabetes 
mellitus, and there was no evidence of an increased risk 
of adverse cardiovascular events (Ball 2004). 
Conclusions
The prevalence of chronic bronchial diseases caused by tobacco 
smoking, namely CB and COPD is great in developed and 
developing countries. Exacerbations constitute the mean cause 
for medical consultation of patients with these diseases and 
bacterial infection is involved in more than half of the cases. Most 
of the microorganisms involved in pathogenesis of exacerbations 
of CB and COPD have developed diverse degrees of resistance 
to the traditional antibiotics used as first-line treatment. 
Development of resistance is caused by the increased volume 
of prescription, the inadequate indication of the antibiotic and/or 
inadequate administration or treatment compliance by the patient. 
Patients with acute (viral) bronchitis and those with exacerbations 
without changes in the volume or characteristics of sputum 
should not be treated with antibiotics. When bacterial infection 
is suspected, there is a growing tendency to treat exacerbations 
more aggressively with shorter courses of antimicrobials to help 
reduce antibiotic resistance (Perez-Gorricho and Ripoll 2003). 
This is possible with the new generation ﬂ  uoroquinolones 
such as moxiﬂ  oxacin. Moxiﬂ  oxacin is a fourth generation 
ﬂ  uoroquinolone that has an excellent in vitro activity against the 
most common respiratory pathogens and its rapid bactericidal 
action allows short-course 5-day therapy for exacerbations of CB 
and COPD. In addition, its long half-life allows administration in 
single daily doses. The once-daily, short-course administration 
guarantees better patient compliance and makes the development 
of resistance less likely.
Moxiﬂ  oxacin is 4- to 10-fold more active than levoﬂ  oxacin 
against S. pneumoniae. A greater intrinsic activity is linked 
Figure 4  Mean cost per patient incurred by treatment failures of exacerbations of CB  and COPD in each group. Derived from Llor et al (2004).
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with faster eradication and reduced susceptibility of the devel-
opment of resistance. In fact, some reports have described the 
development of resistance of S. pneumoniae during treatment 
with levoﬂ  oxacin (Davidson et al 2002), but no reports have 
shown the same phenomenon in patients treated with more 
active ﬂ  uoroquinolones such as moxiﬂ  oxacin or gatiﬂ  oxacin. 
Therefore, these ﬁ  ndings support the concept of “use the best 
ﬁ  rst”. The most potent agent of the class should be used as 
ﬁ  rst line therapy to avoid the development of resistance to 
the entire class of antimicrobials, particularly in moderate 
to severe cases or those with risk factors for relapse or poor 
compliance. 
Moxiﬂ  oxacin has demonstrated better eradication in 
exacerbations of CB and COPD compared to standard 
therapy, in particular compared to macrolides. The complete 
eradication of bacteria present in the airways is important 
for the prevention of resistance development (Stratton 2003) 
and for clinical outcome. The persistence of bacteria after 
antibiotic treatment of an exacerbation has been associated 
with increased inflammation, poorer evolution of the 
baseline disease and early recurrence of exacerbation. Fast 
and complete eradication of bacteria may induce a “virtuous 
circle” preserving and/or restoring the integrity of the 
bronchial mucosa and making it more resistant to further 
bacterial colonization and the development of exacerbations. 
In addition, the reduction in the frequency of exacerbations 
will contribute to preserve pulmonary function and health 
status (De Benedetto and Sevieri 2006) (Figure 5). In the 
MOSAIC trial, patients treated with moxiﬂ  oxacin showed 
a signiﬁ  cantly better eradication, together with an extended 
time to the next exacerbation compared with the standard 
treatments.
The results obtained in registration trials of patients with 
exacerbations of CB and COPD, together with the new trials 
performed after launching moxiﬂ  oxacin have had an impact 
on the development of guidelines of antibacterial treatment of 
exacerbations. The Canadian guidelines indicate ﬂ  uoroquino-
lones as the ﬁ  rst-line treatment for patients with exacerbated 
CB with risk factors (FEV1 <50% predicted, more than 4 
exacerbations/year, cardiac disease, use of home oxygen, 
chronic steroid use or antibiotic use in the past 3 months) and 
second-line therapy in uncomplicated CB (Balter et al 2003). 
The Latin American guidelines recommend moxiﬂ  oxacin as 
ﬁ  rst-line therapy in exacerbated COPD patients with FEV1 
between 35% to 50%, those with an FEV1 <35% without 
risk factors for Pseudomonas infection and those with FEV1 
>50% with risk factors (ALAT Work Group 2004). Recent 
guidelines published in Spain by the Spanish Society of Pneu-
mologists and Thoracic Surgeons and the Spanish Society of 
Geriatrics recommend moxiﬂ  oxacin as ﬁ  rst-line therapy in 
patients with suspected bacterial exacerbation of COPD with 
an FEV1 <50% predicted and without risk factors for Pseu-
domonas infection and in patients with FEV1 >50% with risk 
factors (Miravitlles and Martín Graczyk 2006) (Figure 6).
The appropriate use of moxiﬂ  oxacin in patients with 
exacerbated chronic bronchial disease and clear criteria of 
Table 5 Clinical success rates with moxiﬂ  oxacin and comparators in patients belonging to risk groups in clinical trials of exacerba-
tions of chronic bronchitis and COPD
Risk factor  Moxiﬂ  oxacin  Comparator/s  p value
Age >60 years  46/51 (90.1%)  47/52 (90.4%)  1.00a
  167/184 (90.8%)  161/181 (89.0%)  0.081b
  145/152 (95.4%)  122/137 (89.1%)  0.048c
More than 3 exacerbations   36/42 (85.7%)  30/35 (85.7%)  1.00a
previous year  138/160 (86.3%)  136/160 (85.0%)  0.043b
  111/118 (84.1%)  103/110 (83.6%)  NSc
Cardiopulmonary comorbidity  22/26 (84.6%)  15/19 (78.9%)  0.74a
  21/25 (84.0%)  19/28 (67.9%)  0.010b
  192/202 (95.0%)  166/185 (89.7%)  0.054c
Concomitant use of oral   33/38 (86.8%)  28/32 (87.5%)  1.00a
corticosteroids  140/160 (87.5%)  105/128 (82%)  0.027b
  48/50 (96%)  37/44 (84.1%)  NSc
FEV1 (%) < 50%  70/119 (58.0%)  69/130 (53.1%)  0.36d
  66/69 (95.6%)  67/69 (97.1%)  NSc
Adapted from Miravitlles et al 2007a.
aStarakis et al (2004); bWilson et al (1999); cSchaberg et al (2001); dWilson et al (2004).
NS = nonsigniﬁ  cant differences; p value not reported in the original publication.International Journal of COPD 2007:2(3) 201
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Exacerbation
Change in sputum color 
or purulence of sputum
Yes
No
No bacterial infection
Search for other causes 
of exacerbation
FEV1 > 50%
Specific treatment
Increase bronchodilator
treatment
Moxifloxacin/Levofloxacin*
Bacterial infection
FEV1 < 50%
Risk factors:
- Cardiac comorbidity
- 3 or more exacerbations/year
-Previous antibiotic treatment 
Amoxicillin-clavulanate Moxifloxacin/Levofloxacin
or  amoxicillin-clavulanate
No Yes
Figure 6  Algorithm of antibiotic treatment of ambulatory patients with exacerbations of COPD from the Spanish Society of Pneumology and Thoracic Surgery (SEPAR) 
and the Spanish Society of Geriatry and Gerontology (SEEG). Derived from Miravitlles and Martín Graczyk (2006).
Note: *Except in patients with risk factors for infection with P. aeruginosa, such as impaired lung function, bronchiectasis, and prior use of antibiotics (Eller et al 1998; 
Miravitlles et al 1999; Monsó et al 2003). 
Fast bacterial killing
Immunomodulatory activity
Complete eradication Complete eradication
Few days with bacteria Few days with bacteria
Reduce inflammation Reduce inflammation
Reduce organ damage Reduce organ damage
C
O
P
D
C
O
P
D
M
O
X
I
F
L
O
X
A
C
I
N
M
O
X
I
F
L
O
X
A
C
I
N
•Less frequent exacerbations
￿Better preserved pulmonary function
￿Improved HRQoL 
￿Less need for symptomatic treatment
￿Fewer hospitalizations
￿Reduction in healthcare costs
Figure 5  The “virtuous circle” of antibiotic treatment of exacerbations of CB and COPD. Derived from De Benedetto and Sevieri (2006).International Journal of COPD 2007:2(3) 203
Moxiﬂ  oxacin in exacerbations of COPD
bacterial infection may improve the short- and long-term 
clinical outcome. Restriction of the use of ﬂ  uoroquinolones, 
such as moxiﬂ  oxacin, in patients with acute bronchitis, 
suspected viral infections or benign infections that can 
be successfully treated with older antibiotics will help to 
preserve the antibacterial activity of the class. The use of 
the most active ﬂ  uoroquinolone ﬁ  rst (“use the best ﬁ  rst”) 
may also contribute to preserve the antibacterial activity 
of all quinolones and allow its use in patients who really 
beneﬁ  t from the better outcome obtained with moxiﬂ  oxacin. 
Physicians need to be familiar with criteria for suspecting 
bacterial infection in exacerbated patients and identify risk 
factors for relapse in order to indicate the use of moxiﬂ  oxacin 
according to local and international guidelines.
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